The CRISPR/Cas9 editing of zebrafish rpl13 gene has been proposed for spondyloepimetaphyseal dysplasia (SEMD-RPL13 type), as recently found in several human families (Costantini et al., 2020). This evidence concerns the gene RPL13 and spondyloepimetaphyseal dysplasia, matrilin-3 type.